XML 68 R60.htm IDEA: XBRL DOCUMENT v3.24.2
Stockholders' Equity - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Sep. 01, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 28, 2024
Jun. 13, 2024
Apr. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]                      
Aggregate intrinsic value of stock options exercised       $ 2,600 $ 700            
Weighted average grant date fair value of share-based awards granted       $ 93.65 $ 86.3            
Weighted average grant date fair value of restricted stock units granted       $ 188.57              
Total unrecognized compensation cost   $ 73,300   $ 73,300              
Unrecognized compensation cost, weighted average remaining requisite service period       2 years 7 months 2 days              
Number of unvested options and restricted stock units   2,267,696   2,267,696              
Forfeited portion of grants [1]       22,027              
Share recalculated value             $ 136        
Stock-based compensation expense   $ 9,214 $ 5,483 $ 17,990 $ 12,737            
Common stock, shares issued   55,902,860   55,902,860           55,766,078  
Scenario Forecast                      
Stockholders Equity Note Disclosure [Line Items]                      
Stock-based compensation expense $ 22,400                    
FlexBiosys                      
Stockholders Equity Note Disclosure [Line Items]                      
Common stock, shares issued                 2,770    
Earnout consideration earned                 20.00%    
Avitide                      
Stockholders Equity Note Disclosure [Line Items]                      
Common stock, shares issued               28,638      
Earnout consideration earned               50.00%      
2018 Plan                      
Stockholders Equity Note Disclosure [Line Items]                      
Common stock shares reserved for Issuance                     2,778,000
Incentive options, vesting period   1,523,889   1,523,889              
Unvested Options                      
Stockholders Equity Note Disclosure [Line Items]                      
Incentive options, vesting period       5 years              
Restricted Stock Units and Performance Stock Units                      
Stockholders Equity Note Disclosure [Line Items]                      
Aggregate intrinsic value of restricted stock units vested       $ 23,500 $ 29,600            
Weighted average grant date fair value of restricted stock units granted       $ 188.57 $ 176.86            
Restricted Stock Unit                      
Stockholders Equity Note Disclosure [Line Items]                      
Closing price of common stock           $ 126.06          
2024 Grants                      
Stockholders Equity Note Disclosure [Line Items]                      
Forfeited portion of grants       32,776              
Stock-based compensation expense   $ 4,400   $ 4,400              
[1] Includes 13,057 options forfeited pursuant to the 2024 Award Amendment discussed above under “Chief Executive Officer Accounting Modifications”.